Loading…

Cross-linking of hard gelatin carbamazepine capsules: effect of dissolution conditions on in vitro drug release

The aim of this study was to determine if the use of both enzyme and surfactant in the dissolution medium changes the in vitro drug release from cross-linked hard gelatin capsules containing a water-insoluble drug. Hard gelatin capsules were cross-linked by a controlled exposure to formaldehyde resu...

Full description

Saved in:
Bibliographic Details
Published in:European journal of pharmaceutical sciences 2003-06, Vol.19 (2), p.129-132
Main Authors: Marchais, Hervé, Cayzeele, Guillaume, Legendre, Jean-Yves, Skiba, Mohamed, Arnaud, Philippe
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c391t-4e0dce3f66b55d0a9542eee453f9186618c1b1243e38989da99b32c1d986bc4b3
cites cdi_FETCH-LOGICAL-c391t-4e0dce3f66b55d0a9542eee453f9186618c1b1243e38989da99b32c1d986bc4b3
container_end_page 132
container_issue 2
container_start_page 129
container_title European journal of pharmaceutical sciences
container_volume 19
creator Marchais, Hervé
Cayzeele, Guillaume
Legendre, Jean-Yves
Skiba, Mohamed
Arnaud, Philippe
description The aim of this study was to determine if the use of both enzyme and surfactant in the dissolution medium changes the in vitro drug release from cross-linked hard gelatin capsules containing a water-insoluble drug. Hard gelatin capsules were cross-linked by a controlled exposure to formaldehyde resulting in different stressed capsules and carbamazepine (CBZ) was chosen as a drug model. In vitro dissolution studies were conducted using simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) with enzymes. Sodium lauryl sulfate (SLS) was added in the dissolution medium at a concentration of 2% m/v both in SGF and SIF with pepsin and pancreatin, respectively. The percentage of CBZ dissolved was reduced by increasing the degree of gelatin cross-linking. For unstressed hard gelatin capsules, 36% of the CBZ was released after 1 h, lowering to 5% for highly stressed hard gelatin capsules in the SGF. A similar effect was observed with SIF. In the case of moderately stressed hard gelatin capsules, addition of enzyme in the dissolution medium enhanced the percentage of CBZ dissolved. The dissolution level increased from 12% to 39% in SGF with pepsin for hard gelatin capsules cross-linked with 1500 ppm formaldehyde. On the contrary, the use of enzyme in the dissolution medium did not increase the dissolution of CBZ from highly stressed hard gelatin capsules. Surprisingly, the addition of SLS in the medium did not allow the release of the CBZ both in SGF and in SIF. The results of this study demonstrate that the use of enzyme in the dissolution medium is justified for moderately cross-linked hard gelatin capsules. However, the action of a surfactant added in the medium containing enzyme remains unclear.
doi_str_mv 10.1016/S0928-0987(03)00070-8
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73368933</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0928098703000708</els_id><sourcerecordid>73368933</sourcerecordid><originalsourceid>FETCH-LOGICAL-c391t-4e0dce3f66b55d0a9542eee453f9186618c1b1243e38989da99b32c1d986bc4b3</originalsourceid><addsrcrecordid>eNqF0E1PHCEYwHHS1NR124_QZi41ehgLw7yAF2M2WpuYeLA9Ewae2aLssPLMbFI_vYw70WNPQPJ7gPwJ-croGaOs_nFPZSFyKkVzQvkppbShufhAFkw0MqdNQT-SxRs5JEeIDwnVoqGfyCErGslKVi1IWMWAmHvXP7p-nYUu-6ujzdbg9eD6zOjY6o1-hq3rIZ22OHrA8wy6DswwcesQgx8HF5IOvXXTDrN0SuM7N8SQ2TiuswgeNMJnctBpj_BlXpfkz_XV79VNfnv389fq8jY3XLIhL4FaA7yr67aqLNWyKgsAKCveSSbqmgnDWlaUHLiQQlotZcsLw6wUdWvKli_J8f7ebQxPI-CgNg4NeK97CCOqhvNaSM4TrPbQTCEidGob3UbHf4pRNZVWr6XVlFFRrl5LK5Hmvs0PjO0G7PvUnDaB7zPQaLTvou6Nw3dXirIRgiV3sXeQcuwcRIXGQW_AupgaKxvcf77yAm15nB0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73368933</pqid></control><display><type>article</type><title>Cross-linking of hard gelatin carbamazepine capsules: effect of dissolution conditions on in vitro drug release</title><source>ScienceDirect Journals</source><creator>Marchais, Hervé ; Cayzeele, Guillaume ; Legendre, Jean-Yves ; Skiba, Mohamed ; Arnaud, Philippe</creator><creatorcontrib>Marchais, Hervé ; Cayzeele, Guillaume ; Legendre, Jean-Yves ; Skiba, Mohamed ; Arnaud, Philippe</creatorcontrib><description>The aim of this study was to determine if the use of both enzyme and surfactant in the dissolution medium changes the in vitro drug release from cross-linked hard gelatin capsules containing a water-insoluble drug. Hard gelatin capsules were cross-linked by a controlled exposure to formaldehyde resulting in different stressed capsules and carbamazepine (CBZ) was chosen as a drug model. In vitro dissolution studies were conducted using simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) with enzymes. Sodium lauryl sulfate (SLS) was added in the dissolution medium at a concentration of 2% m/v both in SGF and SIF with pepsin and pancreatin, respectively. The percentage of CBZ dissolved was reduced by increasing the degree of gelatin cross-linking. For unstressed hard gelatin capsules, 36% of the CBZ was released after 1 h, lowering to 5% for highly stressed hard gelatin capsules in the SGF. A similar effect was observed with SIF. In the case of moderately stressed hard gelatin capsules, addition of enzyme in the dissolution medium enhanced the percentage of CBZ dissolved. The dissolution level increased from 12% to 39% in SGF with pepsin for hard gelatin capsules cross-linked with 1500 ppm formaldehyde. On the contrary, the use of enzyme in the dissolution medium did not increase the dissolution of CBZ from highly stressed hard gelatin capsules. Surprisingly, the addition of SLS in the medium did not allow the release of the CBZ both in SGF and in SIF. The results of this study demonstrate that the use of enzyme in the dissolution medium is justified for moderately cross-linked hard gelatin capsules. However, the action of a surfactant added in the medium containing enzyme remains unclear.</description><identifier>ISSN: 0928-0987</identifier><identifier>EISSN: 1879-0720</identifier><identifier>DOI: 10.1016/S0928-0987(03)00070-8</identifier><identifier>PMID: 12791415</identifier><language>eng</language><publisher>Shannon: Elsevier B.V</publisher><subject>Anticonvulsants. Antiepileptics. Antiparkinson agents ; Biological and medical sciences ; Capsules ; Carbamazepine ; Carbamazepine - chemistry ; Carbamazepine - pharmacokinetics ; Cross-linking ; Cross-Linking Reagents - chemistry ; Cross-Linking Reagents - pharmacokinetics ; Dissolution with sodium lauryl sulfate ; Enzymes ; Gelatin ; General pharmacology ; Hard gelatin capsule ; Medical sciences ; Neuropharmacology ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology. Drug treatments ; Solubility</subject><ispartof>European journal of pharmaceutical sciences, 2003-06, Vol.19 (2), p.129-132</ispartof><rights>2003 Elsevier Science B.V.</rights><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c391t-4e0dce3f66b55d0a9542eee453f9186618c1b1243e38989da99b32c1d986bc4b3</citedby><cites>FETCH-LOGICAL-c391t-4e0dce3f66b55d0a9542eee453f9186618c1b1243e38989da99b32c1d986bc4b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=14847881$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12791415$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Marchais, Hervé</creatorcontrib><creatorcontrib>Cayzeele, Guillaume</creatorcontrib><creatorcontrib>Legendre, Jean-Yves</creatorcontrib><creatorcontrib>Skiba, Mohamed</creatorcontrib><creatorcontrib>Arnaud, Philippe</creatorcontrib><title>Cross-linking of hard gelatin carbamazepine capsules: effect of dissolution conditions on in vitro drug release</title><title>European journal of pharmaceutical sciences</title><addtitle>Eur J Pharm Sci</addtitle><description>The aim of this study was to determine if the use of both enzyme and surfactant in the dissolution medium changes the in vitro drug release from cross-linked hard gelatin capsules containing a water-insoluble drug. Hard gelatin capsules were cross-linked by a controlled exposure to formaldehyde resulting in different stressed capsules and carbamazepine (CBZ) was chosen as a drug model. In vitro dissolution studies were conducted using simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) with enzymes. Sodium lauryl sulfate (SLS) was added in the dissolution medium at a concentration of 2% m/v both in SGF and SIF with pepsin and pancreatin, respectively. The percentage of CBZ dissolved was reduced by increasing the degree of gelatin cross-linking. For unstressed hard gelatin capsules, 36% of the CBZ was released after 1 h, lowering to 5% for highly stressed hard gelatin capsules in the SGF. A similar effect was observed with SIF. In the case of moderately stressed hard gelatin capsules, addition of enzyme in the dissolution medium enhanced the percentage of CBZ dissolved. The dissolution level increased from 12% to 39% in SGF with pepsin for hard gelatin capsules cross-linked with 1500 ppm formaldehyde. On the contrary, the use of enzyme in the dissolution medium did not increase the dissolution of CBZ from highly stressed hard gelatin capsules. Surprisingly, the addition of SLS in the medium did not allow the release of the CBZ both in SGF and in SIF. The results of this study demonstrate that the use of enzyme in the dissolution medium is justified for moderately cross-linked hard gelatin capsules. However, the action of a surfactant added in the medium containing enzyme remains unclear.</description><subject>Anticonvulsants. Antiepileptics. Antiparkinson agents</subject><subject>Biological and medical sciences</subject><subject>Capsules</subject><subject>Carbamazepine</subject><subject>Carbamazepine - chemistry</subject><subject>Carbamazepine - pharmacokinetics</subject><subject>Cross-linking</subject><subject>Cross-Linking Reagents - chemistry</subject><subject>Cross-Linking Reagents - pharmacokinetics</subject><subject>Dissolution with sodium lauryl sulfate</subject><subject>Enzymes</subject><subject>Gelatin</subject><subject>General pharmacology</subject><subject>Hard gelatin capsule</subject><subject>Medical sciences</subject><subject>Neuropharmacology</subject><subject>Pharmaceutical technology. Pharmaceutical industry</subject><subject>Pharmacology. Drug treatments</subject><subject>Solubility</subject><issn>0928-0987</issn><issn>1879-0720</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><recordid>eNqF0E1PHCEYwHHS1NR124_QZi41ehgLw7yAF2M2WpuYeLA9Ewae2aLssPLMbFI_vYw70WNPQPJ7gPwJ-croGaOs_nFPZSFyKkVzQvkppbShufhAFkw0MqdNQT-SxRs5JEeIDwnVoqGfyCErGslKVi1IWMWAmHvXP7p-nYUu-6ujzdbg9eD6zOjY6o1-hq3rIZ22OHrA8wy6DswwcesQgx8HF5IOvXXTDrN0SuM7N8SQ2TiuswgeNMJnctBpj_BlXpfkz_XV79VNfnv389fq8jY3XLIhL4FaA7yr67aqLNWyKgsAKCveSSbqmgnDWlaUHLiQQlotZcsLw6wUdWvKli_J8f7ebQxPI-CgNg4NeK97CCOqhvNaSM4TrPbQTCEidGob3UbHf4pRNZVWr6XVlFFRrl5LK5Hmvs0PjO0G7PvUnDaB7zPQaLTvou6Nw3dXirIRgiV3sXeQcuwcRIXGQW_AupgaKxvcf77yAm15nB0</recordid><startdate>20030601</startdate><enddate>20030601</enddate><creator>Marchais, Hervé</creator><creator>Cayzeele, Guillaume</creator><creator>Legendre, Jean-Yves</creator><creator>Skiba, Mohamed</creator><creator>Arnaud, Philippe</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20030601</creationdate><title>Cross-linking of hard gelatin carbamazepine capsules: effect of dissolution conditions on in vitro drug release</title><author>Marchais, Hervé ; Cayzeele, Guillaume ; Legendre, Jean-Yves ; Skiba, Mohamed ; Arnaud, Philippe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c391t-4e0dce3f66b55d0a9542eee453f9186618c1b1243e38989da99b32c1d986bc4b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Anticonvulsants. Antiepileptics. Antiparkinson agents</topic><topic>Biological and medical sciences</topic><topic>Capsules</topic><topic>Carbamazepine</topic><topic>Carbamazepine - chemistry</topic><topic>Carbamazepine - pharmacokinetics</topic><topic>Cross-linking</topic><topic>Cross-Linking Reagents - chemistry</topic><topic>Cross-Linking Reagents - pharmacokinetics</topic><topic>Dissolution with sodium lauryl sulfate</topic><topic>Enzymes</topic><topic>Gelatin</topic><topic>General pharmacology</topic><topic>Hard gelatin capsule</topic><topic>Medical sciences</topic><topic>Neuropharmacology</topic><topic>Pharmaceutical technology. Pharmaceutical industry</topic><topic>Pharmacology. Drug treatments</topic><topic>Solubility</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Marchais, Hervé</creatorcontrib><creatorcontrib>Cayzeele, Guillaume</creatorcontrib><creatorcontrib>Legendre, Jean-Yves</creatorcontrib><creatorcontrib>Skiba, Mohamed</creatorcontrib><creatorcontrib>Arnaud, Philippe</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pharmaceutical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Marchais, Hervé</au><au>Cayzeele, Guillaume</au><au>Legendre, Jean-Yves</au><au>Skiba, Mohamed</au><au>Arnaud, Philippe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cross-linking of hard gelatin carbamazepine capsules: effect of dissolution conditions on in vitro drug release</atitle><jtitle>European journal of pharmaceutical sciences</jtitle><addtitle>Eur J Pharm Sci</addtitle><date>2003-06-01</date><risdate>2003</risdate><volume>19</volume><issue>2</issue><spage>129</spage><epage>132</epage><pages>129-132</pages><issn>0928-0987</issn><eissn>1879-0720</eissn><abstract>The aim of this study was to determine if the use of both enzyme and surfactant in the dissolution medium changes the in vitro drug release from cross-linked hard gelatin capsules containing a water-insoluble drug. Hard gelatin capsules were cross-linked by a controlled exposure to formaldehyde resulting in different stressed capsules and carbamazepine (CBZ) was chosen as a drug model. In vitro dissolution studies were conducted using simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) with enzymes. Sodium lauryl sulfate (SLS) was added in the dissolution medium at a concentration of 2% m/v both in SGF and SIF with pepsin and pancreatin, respectively. The percentage of CBZ dissolved was reduced by increasing the degree of gelatin cross-linking. For unstressed hard gelatin capsules, 36% of the CBZ was released after 1 h, lowering to 5% for highly stressed hard gelatin capsules in the SGF. A similar effect was observed with SIF. In the case of moderately stressed hard gelatin capsules, addition of enzyme in the dissolution medium enhanced the percentage of CBZ dissolved. The dissolution level increased from 12% to 39% in SGF with pepsin for hard gelatin capsules cross-linked with 1500 ppm formaldehyde. On the contrary, the use of enzyme in the dissolution medium did not increase the dissolution of CBZ from highly stressed hard gelatin capsules. Surprisingly, the addition of SLS in the medium did not allow the release of the CBZ both in SGF and in SIF. The results of this study demonstrate that the use of enzyme in the dissolution medium is justified for moderately cross-linked hard gelatin capsules. However, the action of a surfactant added in the medium containing enzyme remains unclear.</abstract><cop>Shannon</cop><pub>Elsevier B.V</pub><pmid>12791415</pmid><doi>10.1016/S0928-0987(03)00070-8</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0928-0987
ispartof European journal of pharmaceutical sciences, 2003-06, Vol.19 (2), p.129-132
issn 0928-0987
1879-0720
language eng
recordid cdi_proquest_miscellaneous_73368933
source ScienceDirect Journals
subjects Anticonvulsants. Antiepileptics. Antiparkinson agents
Biological and medical sciences
Capsules
Carbamazepine
Carbamazepine - chemistry
Carbamazepine - pharmacokinetics
Cross-linking
Cross-Linking Reagents - chemistry
Cross-Linking Reagents - pharmacokinetics
Dissolution with sodium lauryl sulfate
Enzymes
Gelatin
General pharmacology
Hard gelatin capsule
Medical sciences
Neuropharmacology
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
Solubility
title Cross-linking of hard gelatin carbamazepine capsules: effect of dissolution conditions on in vitro drug release
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T16%3A23%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cross-linking%20of%20hard%20gelatin%20carbamazepine%20capsules:%20effect%20of%20dissolution%20conditions%20on%20in%20vitro%20drug%20release&rft.jtitle=European%20journal%20of%20pharmaceutical%20sciences&rft.au=Marchais,%20Herv%C3%A9&rft.date=2003-06-01&rft.volume=19&rft.issue=2&rft.spage=129&rft.epage=132&rft.pages=129-132&rft.issn=0928-0987&rft.eissn=1879-0720&rft_id=info:doi/10.1016/S0928-0987(03)00070-8&rft_dat=%3Cproquest_cross%3E73368933%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c391t-4e0dce3f66b55d0a9542eee453f9186618c1b1243e38989da99b32c1d986bc4b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=73368933&rft_id=info:pmid/12791415&rfr_iscdi=true